Join to View Full Profile
1124 Columbia StSte 300Seattle, WA 98104
Phone+1 301-928-4067
Dr. Lechleider is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1992
University of Illinois College of MedicineClass of 1990
National Institutes of Health Clinical CenterFellowship, Medical Oncology
Certifications & Licensure
MD State Medical License 1999 - 2018
Clinical Trials
- Safety Study of MGAH22 in HER2-positive Carcinomas
- Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
- Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) Start of enrollment: 2014 Jun 09
- Join now to see all
Publications & Presentations
PubMed
- 170 citationsFirst-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumorsYung-Jue Bang, Giuseppe Giaccone, Seock-Ah Im, Do Youn Oh, Todd M. Bauer
Annals of Oncology. 2017-04-01 - 14 citationsCirculating Tumor Cells: Application as a Biomarker for Molecular Characterization and Predictor of Survival in an All-Comer Solid Tumor Phase I Clinical StudyHaifeng Bao, Patricia Burke, Jiaqi Huang, Xiaoru Chen, Philip Brohawn
Plos One. 2013-08-21 - 86 citationsPhase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsChristina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole D. Houston, Robert L. Coleman
Investigational New Drugs. 2013-02-01
Press Mentions
Seattle Genetics Announces Data Presentations at 2018 ASCO Annual MeetingMay 17th, 2018- Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial CancerMarch 26th, 2018
- Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple MyelomaMarch 7th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
